{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-104032","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-09-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.751474+00:00","generated_at":"2026-05-31T06:12:18.049662+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"KalVista Q1 net loss $40.4M; FDA accepts NDA for sebetralstat, PDUFA June 17, 2025","bullets":["Net loss $40.4M ($0.87/share) vs $25.3M prior year; no revenue recognized.","Cash and securities $174.3M at July 31, down from $210.4M on April 30.","FDA accepted NDA for oral sebetralstat for HAE; PDUFA goal date June 17, 2025.","EMA validated MAA submission for sebetralstat; UK/Japan filings planned later in 2024.","Phase 3 KONFIDENT-KID pediatric trial initiated dosing with oral disintegrating tablet."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-104032","json":"https://secwatch.observer/filing/0000950170-24-104032.json","markdown":"https://secwatch.observer/filing/0000950170-24-104032.md","text":"https://secwatch.observer/filing/0000950170-24-104032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024104032/0000950170-24-104032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024104032/kalv-20240905.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:12:18.049662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}